Stoke Therapeutics and Biogen Report First Patient Dosing in P-III (EMPEROR) Trial of Zorevunersen for Dravet Syndrome

Shots:Stoke Therapeutics & Biogen have dosed their first patient with zorevunersen in global P-III (EMPEROR) trial for the treatment of Dravet syndrome; Trial has initiated in the US, UK, & Japan, with an EU study plannedTrial will assess zorevunersen (70mg on Day 1 & Wk. 8, then 45mg at Wks. 24 & 40) vs sham…

ByRidhi RastogiAugust 12, 2025

NEWS

Biogen Collaborates with Stoke Therapeutics to Develop and Commercialize Zorevunersen for Dravet Syndrome

Shots:Biogen & Stoke have partnered to develop & market zorevunersen for Dravet syndrome with Stoke retaining rights in the US, Canada, & Mexico while leading global development & Biogen securing marketing rights in other regions As per the deal, Stoke will get $165M upfront, ~$385M in development & commercial milestones, & net sales-based…

ByRidhi RastogiFebruary 19, 2025

VIEWPOINTS

PharmaShots Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

In an interview with PharmaShots, Bradley Galer, M.D., Chief Medical Officer at Zogenix shed light on data supporting the regulatory application and what the EU approval of Fintepla will mean in terms of reducing the high physical, emotional, and financial burden associated with the disease.Shots:Fintepla was approved by the EC in Dec'2020 as a new add-on therapy to…

BySenior EditorFebruary 16, 2021

Stoke Therapeutics and Biogen Report First Patient Dosing in P-III (EMPEROR) Trial of Zorevunersen for Dravet Syndrome

Biogen Collaborates with Stoke Therapeutics to Develop and Commercialize Zorevunersen for Dravet Syndrome

PharmaShots Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

Contact US

OUR INFORMATION

FOLLOW US